On March 23, 2026, Ensysce Biosciences, Inc. filed an 8-K form with the SEC, detailing a Certificate of Correction (CoC) related to its Series B Preferred Stock. This filing corrects a scrivener's error in the previously filed Certificate of Designation of Series B Preferred Stock, which was originally submitted on November 14, 2025. The correction is administrative in nature and does not alter the substantive rights of the shareholders or the terms of the preferred stock. The CoC is attached as Exhibit 3.1 to the filing. This action is part of the company's ongoing efforts to ensure compliance with regulatory requirements and maintain accurate corporate governance documentation. The filing indicates that the current fiscal year will end on December 31, 2026, and confirms the company's incorporation in Delaware with a Central Index Key (CIK) of 0001716947. The document also includes standard disclosures regarding the company's address and contact information, which remains unchanged. Overall, this filing is expected to have a neutral impact on the company's stock price as it addresses a clerical issue rather than a material change in operations or financial condition.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.